Remix Therapeutics
Our Science
Platform
Pipeline
About Us
Our Story
Our People
Our Investors
Our Partners
Join Us
News
News
Press Releases
Publications
Clinical Trials
Our Science
Platform
Pipeline
About Us
Our Story
Our People
Our Investors
Our Partners
Join Us
News
News
Press Releases
Publications
Clinical Trials
Contact
Feb | 17 | 2022
News
Remix Therapeutics signs Janssen licensing deal that could top $1B
by Max Bayer, Fierce Biotech
Read Article
Back to News
Media Contact
PEG RUSCONI
Deerfield Group
Peg.Rusconi@deerfieldgroup.com
Investor Contact
WILL O’CONNOR
Precision AQ
Will.OConnor@precisionaq.com